Faced with increasing prescription drug costs and congressional gridlock, some states have enacted meaningful reforms. In April 2017, New York State became the first public payer in the United States to authorize limits on prescription drug costs based on their therapeutic benefits.1 Under its new budget legislation, the state can identify high-cost drugs, determine a value-based price, and use enhanced powers to negotiate supplemental rebates to achieve this target price for its Medicaid program. New York’s Medicaid program is the second-largest in the United States, covering approximately 6 million beneficiaries who account for 10% of national Medicaid drug expenditures.2 This Viewpoint discusses New York’s novel approach to addressing drug costs and assesses the potential effect of this value-based pricing system.
Hwang TJ, Kesselheim AS, Sarpatwari A. Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA. 2017;318(7):609–610. doi:10.1001/jama.2017.8255
Customize your JAMA Network experience by selecting one or more topics from the list below.